Les résultats et les conclusions des travaux menés par l’écosystème Experts Recherche Lymphome sont publiés dans des journaux médicaux de premier plan.
Lysa
2026_End-of-induction circulating tumor DNA outperforms conventional cellular MRD for predicting early progression in follicular lymphoma: an ancillary study of the RELEVANCE randomized trial.
Blood Cancer J 2026.
En savoir plus
Lysa
2026_SENIOR-IPI: An easily applicable prognostic index for first-line large B-cell lymphomas patients >80 years treated with curative intent.
Br J Haematol 2026.
En savoir plus
Lysa
2026_Constructing an External Control Arm Using the French REALYSA Cohort to Replicate Outcomes of a Randomized Trial Arm in Advanced Hodgkin Lymphoma.
Clin Pharmacol Ther 2026.
En savoir plus
Lysa
2026_Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real-World Analysis From REALYSA, a LYSA Cohort.
Hematol Oncol 2026;44:e70264.
En savoir plus
Lysa
2026_Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era.
Br J Haematol 2026.
En savoir plus
Lysa
2026_ Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.
Bone Marrow Transplant 2026:1–7.
En savoir plus
Lysa
2026_Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin’s lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial.
Haematologica 2026.
En savoir plus
Lysa
2026_Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study.
Eur J Nucl Med Mol Imaging 2026.
En savoir plus
Lysa
2026_Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.
Blood Adv 2026;10:4455–67.
En savoir plus
Lysa
2026_Hemophagocytic lymphohistiocytosis-like syndrome after CD19-directed CAR T-cells for B-cell lymphoma and B-cell acute lymphoblastic leukemia: A LYSA, SFCE, and GRAALL study from the DESCAR-T registry.
Hemasphere 2026;10:e70425.
En savoir plus
Lysa
2026_Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.
Blood 2026;147:3061–8.
En savoir plus
Lysa
2026_Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.
Haematologica 2026.
En savoir plus
Lysa
2026_Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma.
Blood Adv 2026:bloodadvances.2026020168.
En savoir plus
Lysa
2026_Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience.
Haematologica 2026.
En savoir plus
Lysa
2026_Anti-CD19 CAR T-cell therapy in relapsed/refractory T-cell/histiocyte-rich large B-cell lymphoma: insights from the French DESCAR-T registry, a LYSA study.
Haematologica 2026.
En savoir plus
Lysa
2026_Approche méthodologique de chaînage indirect des données de la cohorte REALYSA de patients porteurs de lymphome et du SNDS
Journal of Epidemiology and Population Health 2026;74:203252.
En savoir plus
Lysa
2026_. Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).
Immunooncol Technol 2026;29:101077.
En savoir plus
Lysa
2026_Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry.
Blood Advances 2026.
En savoir plus
Lysa
2026_Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy.
Blood Cancer J 2026;16:22.
En savoir plus
Lysa
2026_Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm
Journal of Hematology & Oncology 2026
En savoir plus
Lysa
2026_Breast implants and cancer: Anaplastic large cell lymphoma in breast implants.
Ann Chir Plast Esthet 2026;71:93–103.
En savoir plus
Lysa
2026_. Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group
HemaSphere 2026;10:e70356.
En savoir plus
Lysa
2026_Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse.
Haematologica 2026.
En savoir plus
Lysa
2025_Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: A DESCAR-T analysis
Hemasphere 2025;9:e70263.
En savoir plus